This trial is testing whether targeted therapy based on a tumor's genetic profile is more effective than standard treatment for metastatic cancer.
1 Primary · 0 Secondary · Reporting Duration: Continuous Monitoring, expected range from 2 months to 3 years
Active Control
Experimental Treatment
1362 Total Participants · 2 Treatment Groups
Primary Treatment: Standard-of-Care Therapy · No Placebo Group · N/A
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: